Bayer and Janssen to present new Xarelto data at 2017 ESC Congress

Bayer and Janssen will be attending this year's European Society of Cardiology (ESC) Congress, where they will be presenting new clinical data on their drug Xarelto.

New data from the landmark phase III COMPASS study will be shared at the conference in Barcelona, which will demonstrate the benefits of Xarelto in the treatment of coronary and peripheral artery disease.

These findings will be among 25 presentations from Janssen and Bayer to be featured at the ESC Congress, with the companies also set to discuss sub-analyses from the PIONEER AF-PCI, which assessed Xarelto in patients with non-valvular atrial fibrillation following percutaneous coronary intervention with stenting.

Dr James List, global therapeutic area head for cardiovascular and metabolism at Janssen, said: "We are excited to share the results of the very important COMPASS study as they provide new insights into the prevention of cardiovascular events in patients treated with Xarelto, the only Factor Xa inhibitor currently under investigation in this population."

The COMPASS trial was being stopped early based on the recommendation of the study's independent data monitoring committee, as it was determined that the primary efficacy endpoint had reached its prespecified criteria for superiority.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.